Exact Mass: 420.2624086

Exact Mass Matches: 420.2624086

Found 64 metabolites which its exact mass value is equals to given mass value 420.2624086, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Testosterone Phenylpropionate

17beta-Hydroxyandrost-4-en-3-one 3-phenylpropionate

C28H36O3 (420.26643060000004)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones

   

tingenone

(6aR,6bR,8aS,11R,12aR,14aR)-3-hydroxy-4,6a,6b,8a,11,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-quinone

C28H36O3 (420.26643060000004)


D000970 - Antineoplastic Agents

   

CPA(18:0/0:0)

(2-Hydroxy-2-oxo-1,3,2λ⁵-dioxaphospholan-4-yl)methyl octadecanoic acid

C21H41O6P (420.26406160000005)


cPA(18:0/0:0) is a cyclic phosphatidic acid or cyclic lysophosphatidic acid. It is a glycerophospholipid in which a cyclic phosphate moiety occupies two glycerol substitution sites. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1). Fatty acids containing 16 and 18 carbons are the most common. Cyclic phosphatidic acids have been detected in a wide range of organisms including humans, especially in the brain but also in serum (at a concentration of 10-7M). cPAs have a cyclic phosphate at the sn-2 and sn-3 positions of the glycerol carbons, and this structure is absolutely necessary for their activities. In particular, it is found in tissues subject to injury, and while it may have some similar signalling functions to lysophosphatidic acid per se, it also has some quite distinct biological activities. For example, cyclic phosphatidic acid is known to be a specific inhibitor of DNA polymerase alpha. It has an appreciable effect on the inhibition of cancer cell invasion and metastasis. [HMDB] cPA(18:0/0:0) is a cyclic phosphatidic acid or cyclic lysophosphatidic acid. It is a glycerophospholipid in which a cyclic phosphate moiety occupies two glycerol substitution sites. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1). Fatty acids containing 16 and 18 carbons are the most common. Cyclic phosphatidic acids have been detected in a wide range of organisms including humans, especially in the brain but also in serum (at a concentration of 10-7M). cPAs have a cyclic phosphate at the sn-2 and sn-3 positions of the glycerol carbons, and this structure is absolutely necessary for their activities. In particular, it is found in tissues subject to injury, and while it may have some similar signalling functions to lysophosphatidic acid per se, it also has some quite distinct biological activities. For example, cyclic phosphatidic acid is known to be a specific inhibitor of DNA polymerase alpha. It has an appreciable effect on the inhibition of cancer cell invasion and metastasis.

   

Testosterone phenylpropionate

2,15-dimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl 3-phenylpropanoate

C28H36O3 (420.26643060000004)


   
   
   
   
   
   
   

CPA(18:0)

1-octadecanoyl-sn-glycero-2,3-cyclic phosphate

C21H41O6P (420.26406160000005)


   

1-oleyl glycerone-3-phosphate

1-(9Z-octadecenyl)-glycerone 3-phosphate

C21H41O6P (420.26406160000005)


   

1-vaccenyl glycerone-3-phosphate

1-(11Z-octadecenyl)-glycerone 3-phosphate

C21H41O6P (420.26406160000005)


   

CPA 18:0

1-octadecanoyl-sn-glycero-2,3-cyclic phosphate

C21H41O6P (420.26406160000005)


   

4-nonyl-2-(4-nonyl-1,3-thiazol-2-yl)-1,3-thiazole

4-nonyl-2-(4-nonyl-1,3-thiazol-2-yl)-1,3-thiazole

C24H40N2S2 (420.263276)


   

tert-Butyl 4-(2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine-1-carboxylat95

tert-Butyl 4-(2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine-1-carboxylat95

C22H34BFN2O4 (420.2595526)


   

Pipebuzone

4-butyl-4-[(4-methylpiperazin-1-yl)methyl]-1,2-diphenylpyrazolidine-3,5-dione

C25H32N4O2 (420.25251319999995)


C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic

   
   

Vascor

Bepridil hydrochloride

C24H37ClN2O2 (420.2543412)


C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker

   

1-Oleylglycerone 3-phosphate

1-Oleylglycerone 3-phosphate

C21H41O6P (420.26406160000005)


A 1-alkylglycerone 3-phosphate in which the alkyl group is specified as oleyl

   

(2R)-2-hydroxy-3-{[(1Z)-octadec-1-en-1-yl]oxy}propyl phosphate

(2R)-2-hydroxy-3-{[(1Z)-octadec-1-en-1-yl]oxy}propyl phosphate

C21H41O6P-2 (420.26406160000005)


   
   
   

N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline hydrochloride--water (1/1)

N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline hydrochloride--water (1/1)

C24H37ClN2O2 (420.2543412)


   

1-[3-(dimethylamino)propyl]-1-[(5,8-dimethyl-2-oxo-1H-quinolin-3-yl)methyl]-3-(phenylmethyl)urea

1-[3-(dimethylamino)propyl]-1-[(5,8-dimethyl-2-oxo-1H-quinolin-3-yl)methyl]-3-(phenylmethyl)urea

C25H32N4O2 (420.25251319999995)


   

(6aS,6bS,8aS,11R,14aR)-3-hydroxy-4,6a,6b,8a,11,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione

(6aS,6bS,8aS,11R,14aR)-3-hydroxy-4,6a,6b,8a,11,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione

C28H36O3 (420.26643060000004)


   

(6aR,6bR,8aS,11R,12aR,14aR)-3-hydroxy-4,6a,6b,8a,11,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione

(6aR,6bR,8aS,11R,12aR,14aR)-3-hydroxy-4,6a,6b,8a,11,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione

C28H36O3 (420.26643060000004)


D000970 - Antineoplastic Agents

   

1-Octadecanoyl-cyclophosphatidic acid

1-Octadecanoyl-cyclophosphatidic acid

C21H41O6P (420.26406160000005)


   

1-stearoyl-cyclic phosphatidic acid

1-stearoyl-cyclic phosphatidic acid

C21H41O6P (420.26406160000005)


   

1-Oleyl-sn-glycero-3-phosphate(2-)

1-Oleyl-sn-glycero-3-phosphate(2-)

C21H41O6P (420.26406160000005)


A 1-alkyl-sn-glycerol 3-phosphate(2-) obtained by deprotonation of the phosphate OH groups of 1-oleyl-sn-glycero-3-phosphate; major species at pH 7.3.

   

1-Octadecylglycerone 3-phosphate(2-)

1-Octadecylglycerone 3-phosphate(2-)

C21H41O6P (420.26406160000005)


A 1-alkylglycerone 3-phosphate(2-) obtained by deprotonation of the phosphate OH groups of 1-octadecylglycerone 3-phosphate; major species at pH 7.3.

   

1-(1Z-octadecenyl)-sn-glycero-3-phosphate(2-)

1-(1Z-octadecenyl)-sn-glycero-3-phosphate(2-)

C21H41O6P (420.26406160000005)


A 1-(Z)-alk-1-enyl-sn-glycero-3-phosphate(2-) obtained by deprotonation of the phosphate OH groups of any 1-(1Z-octadecenyl)-sn-glycero-3-phosphate; major species at pH 7.3.

   
   
   

(6bs,8ar,11s,12as,12br,14as)-3-hydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione

(6bs,8ar,11s,12as,12br,14as)-3-hydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione

C28H36O3 (420.26643060000004)


   

4,6,16-trihydroxy-9,12,13-trimethyl-14-(2-methylpropyl)-2h,3h,4h,6h,7h,8h,10ah,13h,13ah,14h-1-oxa-2-azacyclododeca[12,11-d]isoindol-5-one

4,6,16-trihydroxy-9,12,13-trimethyl-14-(2-methylpropyl)-2h,3h,4h,6h,7h,8h,10ah,13h,13ah,14h-1-oxa-2-azacyclododeca[12,11-d]isoindol-5-one

C23H36N2O5 (420.2624086)


   

(4s,6r,10as,13s,13as,14s,16ar)-4,6,16-trihydroxy-9,12,13-trimethyl-14-(2-methylpropyl)-2h,3h,4h,6h,7h,8h,10ah,13h,13ah,14h-1-oxa-2-azacyclododeca[11,12-d]isoindol-5-one

(4s,6r,10as,13s,13as,14s,16ar)-4,6,16-trihydroxy-9,12,13-trimethyl-14-(2-methylpropyl)-2h,3h,4h,6h,7h,8h,10ah,13h,13ah,14h-1-oxa-2-azacyclododeca[11,12-d]isoindol-5-one

C23H36N2O5 (420.2624086)


   

(6bs,8as,11r,12ar,12bs,14ar)-3-hydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione

(6bs,8as,11r,12ar,12bs,14ar)-3-hydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione

C28H36O3 (420.26643060000004)


   

6-oxo-iguesterol

NA

C28H36O3 (420.26643060000004)


{"Ingredient_id": "HBIN012737","Ingredient_name": "6-oxo-iguesterol","Alias": "NA","Ingredient_formula": "C28H36O3","Ingredient_Smile": "CC1=CCC2(CCC3(C4=CC(=O)C5=C(C(=C(C=C5C4(CCC3(C2C1)C)C)O)O)C)C)C","Ingredient_weight": "420.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "16348","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "10342107","DrugBank_id": "NA"}

   

(6bs,8as,12ar,12bs,14ar)-2,3-dihydroxy-4,6b,8a,11,12b,14a-hexamethyl-8,9,12,12a,13,14-hexahydro-7h-picen-5-one

(6bs,8as,12ar,12bs,14ar)-2,3-dihydroxy-4,6b,8a,11,12b,14a-hexamethyl-8,9,12,12a,13,14-hexahydro-7h-picen-5-one

C28H36O3 (420.26643060000004)


   

2,10a-dihydroxy-1,4b,6a,8-tetramethyl-8-(4-methylpenta-1,3-dien-1-yl)-6,7,9,10-tetrahydro-5h-chrysen-3-one

2,10a-dihydroxy-1,4b,6a,8-tetramethyl-8-(4-methylpenta-1,3-dien-1-yl)-6,7,9,10-tetrahydro-5h-chrysen-3-one

C28H36O3 (420.26643060000004)


   

(6bs,8as,12as,12bs,14ar)-3-hydroxy-8a-(hydroxymethyl)-4,6b,12b,14a-tetramethyl-11-methylidene-7,8,9,10,12,12a,13,14-octahydropicen-2-one

(6bs,8as,12as,12bs,14ar)-3-hydroxy-8a-(hydroxymethyl)-4,6b,12b,14a-tetramethyl-11-methylidene-7,8,9,10,12,12a,13,14-octahydropicen-2-one

C28H36O3 (420.26643060000004)


   

(2r,4as,6as,6bs,14as,14br)-10,11-dihydroxy-2,4a,6a,6b,9,14a-hexamethyl-2,4,5,6,14,14b-hexahydro-1h-picen-3-one

(2r,4as,6as,6bs,14as,14br)-10,11-dihydroxy-2,4a,6a,6b,9,14a-hexamethyl-2,4,5,6,14,14b-hexahydro-1h-picen-3-one

C28H36O3 (420.26643060000004)


   

(8as,10s,11s,12ar,12bs,14as)-3,10-dihydroxy-4,7,8a,11,12b,14a-hexamethyl-8,9,10,11,12,12a,13,14-octahydropicen-2-one

(8as,10s,11s,12ar,12bs,14as)-3,10-dihydroxy-4,7,8a,11,12b,14a-hexamethyl-8,9,10,11,12,12a,13,14-octahydropicen-2-one

C28H36O3 (420.26643060000004)


   

10,11-dihydroxy-2,4a,6a,6b,9,14a-hexamethyl-2,4,5,6,14,14b-hexahydro-1h-picen-3-one

10,11-dihydroxy-2,4a,6a,6b,9,14a-hexamethyl-2,4,5,6,14,14b-hexahydro-1h-picen-3-one

C28H36O3 (420.26643060000004)


   

(6bs,8as,11r,12ar,14ar)-3-hydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione

(6bs,8as,11r,12ar,14ar)-3-hydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione

C28H36O3 (420.26643060000004)


   

3-hydroxy-4,6b,8a,12b,14a-pentamethyl-11-methylidene-7,8,9,10,12,12a,13,14-octahydro-6ah-picene-2,6-dione

3-hydroxy-4,6b,8a,12b,14a-pentamethyl-11-methylidene-7,8,9,10,12,12a,13,14-octahydro-6ah-picene-2,6-dione

C28H36O3 (420.26643060000004)


   

2,3-dihydroxy-4,6b,8a,11,12b,14a-hexamethyl-8,9,12,12a,13,14-hexahydro-7h-picen-5-one

2,3-dihydroxy-4,6b,8a,11,12b,14a-hexamethyl-8,9,12,12a,13,14-hexahydro-7h-picen-5-one

C28H36O3 (420.26643060000004)


   

2,3-dihydroxy-4,6b,8a,12b,14a-pentamethyl-11-methylidene-7,8,9,10,12,12a,13,14-octahydropicen-5-one

2,3-dihydroxy-4,6b,8a,12b,14a-pentamethyl-11-methylidene-7,8,9,10,12,12a,13,14-octahydropicen-5-one

C28H36O3 (420.26643060000004)


   

(8as,10s,11r,12ar,12bs,14as)-3,10-dihydroxy-4,7,8a,11,12b,14a-hexamethyl-8,9,10,11,12,12a,13,14-octahydropicen-2-one

(8as,10s,11r,12ar,12bs,14as)-3,10-dihydroxy-4,7,8a,11,12b,14a-hexamethyl-8,9,10,11,12,12a,13,14-octahydropicen-2-one

C28H36O3 (420.26643060000004)


   

3,10-dihydroxy-4,7,8a,11,12b,14a-hexamethyl-8,9,10,11,12,12a,13,14-octahydropicen-2-one

3,10-dihydroxy-4,7,8a,11,12b,14a-hexamethyl-8,9,10,11,12,12a,13,14-octahydropicen-2-one

C28H36O3 (420.26643060000004)


   

(6bs,8as,11r,12ar,12br,14ar)-3-hydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione

(6bs,8as,11r,12ar,12br,14ar)-3-hydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione

C28H36O3 (420.26643060000004)


   

(4bs,6as,8r,10ar)-2,10a-dihydroxy-1,4b,6a,8-tetramethyl-8-[(1e)-4-methylpenta-1,3-dien-1-yl]-6,7,9,10-tetrahydro-5h-chrysen-3-one

(4bs,6as,8r,10ar)-2,10a-dihydroxy-1,4b,6a,8-tetramethyl-8-[(1e)-4-methylpenta-1,3-dien-1-yl]-6,7,9,10-tetrahydro-5h-chrysen-3-one

C28H36O3 (420.26643060000004)


   

(6ar,6br,8ar,12ar,12bs,14ar)-3-hydroxy-4,6b,8a,12b,14a-pentamethyl-11-methylidene-7,8,9,10,12,12a,13,14-octahydro-6ah-picene-2,6-dione

(6ar,6br,8ar,12ar,12bs,14ar)-3-hydroxy-4,6b,8a,12b,14a-pentamethyl-11-methylidene-7,8,9,10,12,12a,13,14-octahydro-6ah-picene-2,6-dione

C28H36O3 (420.26643060000004)


   

(6bs,8ar,12ar,12bs,14ar)-2,3-dihydroxy-4,6b,8a,12b,14a-pentamethyl-11-methylidene-7,8,9,10,12,12a,13,14-octahydropicen-5-one

(6bs,8ar,12ar,12bs,14ar)-2,3-dihydroxy-4,6b,8a,12b,14a-pentamethyl-11-methylidene-7,8,9,10,12,12a,13,14-octahydropicen-5-one

C28H36O3 (420.26643060000004)


   

(6bs,8as,11r,12bs,14ar)-3-hydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione

(6bs,8as,11r,12bs,14ar)-3-hydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione

C28H36O3 (420.26643060000004)


   

(1r,5r,8r)-8-[(1r,3as,3bs,9bs,11as)-6,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one

(1r,5r,8r)-8-[(1r,3as,3bs,9bs,11as)-6,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one

C28H36O3 (420.26643060000004)


   

3-hydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione

3-hydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione

C28H36O3 (420.26643060000004)


   

(6bs,8as,11s,12ar,12bs,14ar)-3-hydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione

(6bs,8as,11s,12ar,12bs,14ar)-3-hydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione

C28H36O3 (420.26643060000004)